TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage change in plasma aldosterone concentration (PAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Treatment failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: bioavailability of loratadine and ambroxol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardioembolic strokes
Endpoint domain: Mortality/survival
Primary endpoint: Embolic strokes of undetermined source
Endpoint domain: Mortality/survival
Primary endpoint: improved functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: brain volume changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative percentage dose recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative needed dose of ketoralac
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: WOSI score for shoulder instability
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: loss of neuroretinal rim
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IgG geometric mean concentrations (GMCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: amount of postpartum bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of adequate compressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion to T2D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: colour-naming times for physical threat cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year TLF event rate
Endpoint domain: Mortality/survival
Primary endpoint: P. aeruginosa eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Infection free period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of platelet aggregation (IPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: nocturnal FFA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vertical ridge height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Horizontal ridge width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: team leader behavioral performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to diabetic status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normalization of glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: QALYs
Endpoint domain: Mortality/survival
Primary endpoint: Probability of target attainment for free drug concentration remaining above the minimum inhibitory concentration (MIC) for 40% or greater of the dosing interval (40% fT > MIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of the movement of thin barium through the hyoid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: moving speed of paste barium through the hyoid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of respiratory events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: EELV (End-expiratory lung volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PaO2 (Partial pressure of oxygen)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Entry site related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Catheter manipulation related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Biochemically confirmed 7-day abstinence at end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of axillary brachial plexus blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain intensity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly cigarette consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery times for FVC, FEV(1) and volume‐adjusted mid‐expiratory flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Full retinal thickness (FRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Generalised increase in breast density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Threshold for objective symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-IFNbeta neutralizing antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Medical complications during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDL(2)-cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HDL(3) cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful management of pneumonia and severe malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readmission to hospital
Endpoint domain: Adverse events/effects
Primary endpoint: Healthcare and societal cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Testicular volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of spontaneous descent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of retained position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State‐Trait Anxiety Inventory scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: fatigue scores on the Profile of Mood States
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: postoperative pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in platelet monocyte aggregates (PMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in TOVA ADHD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate to MDX 1400 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of eyes with gains in BCVA of 15 or more ETDRS letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reductions in CRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident HIV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incident depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Polysomnographic indices of OSA severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum HSP27 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum Aβ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: User acceptability of ABHRs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective skin tolerability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effectiveness of NNS in primary care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative ileus and gastrointestinal transit normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean chest compression interruption time to apply the ACC device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean chest compression interruption time to remove the ACC device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SBS of SE in root dentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stage of change regarding body posture and workstation adjustment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: self-reported use of breaks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: significantly effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of TCM symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of acute renal failure requiring hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Bet size after losses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of vomiting at 72 h
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: ASAS 20 achievement at week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADC (Apparent Diffusion Coefficient)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: f(enh) (enhancement fraction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: g(enh) (enhancement rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive nitrogen balance recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total protein and albumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptoms of ADHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: color perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scotopic contrast sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: photopic contrast sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target engagement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of shots fired
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of early response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of heart failure (HF)
Endpoint domain: Mortality/survival
Primary endpoint: Functional Mobility Evaluation (FME)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Barthel Index (MBI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Amplitude of SEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of unpractised exemplars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: NK cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: beta2-microglobulin serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sIL-2r serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: fewer cases of tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lower standardized heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lower standardized SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HIV transmission risk appraisal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario McMaster osteoarthritis index score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Progression of the center of pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of abduction strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Risk of bothersome soreness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of injuries to muscles, ligaments and tendons
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Derkay Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voice Handicap Index scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Success rate of macular hole closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean improvement in visual acuity (ETDRS letters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Executive function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: low/high frequency ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of clinical stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean level of mania symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time with significant mania symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum lipoprotein(a) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RTI-related hospital admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Days of RTI-related outpatient intravenous antibiotic therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cost of treating RTIs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean daily total insulin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Definite or probable stent thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: family conflict
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Likelihood of being obese
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Likelihood of having a high WHR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Likelihood of having a high WC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Primary patency at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Primary-assisted patency at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Cost of maintaining RSFE patency
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average change in pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: osmotic diarrhoea
Endpoint domain: Adverse events/effects
Primary endpoint: febrile respiratory illnesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of pulse irregularity and variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: deterioration in sensory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total faecal SCFAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total number of bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Zung's Self‐Rating Depression Scale (ZSDS) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: State‐Anxiety (STAI‐1) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Trait‐Anxiety (STAI‐2) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean serum 25‐OH‐D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of GDM
Endpoint domain: Adverse events/effects
Primary endpoint: Disease-Free Survival (DFS) rate at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Median Disease-Free Survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Grade 3 or 4 neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Lean mass increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Castration levels achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PSA levels reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adverse events associated with bicalutamide
Endpoint domain: Adverse events/effects
Primary endpoint: Temperature of inhaled gas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute humidity of inhaled gas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End diastolic area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: End systolic area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Parent-reported treatment gains
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean decline in YMRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct diagnoses submitted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lumbar spine BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: proximal femur BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: appendicular skeletal muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Loss to follow up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postoperative shivering
Endpoint domain: Adverse events/effects
Primary endpoint: Evidence of practice score
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: change in body fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Healing time for mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of uncovered struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Conversion to NSR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Atrial transport function (ATF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean adult height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy in curing malaria infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevention of recrudescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Suppression of gametocytaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Contrast-induced nephropathy incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cystatin-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Level of IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: self-stigma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: proactive coping with societal stigma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Risk for ADHD in relatives
Endpoint domain: Mortality/survival
Primary endpoint: Risk for PSUD in relatives
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of positive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of negative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Miosis (pupil constriction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of pupillary reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latency of pupillary reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in local pulmonary vascular resistance (PVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes